Summit Therapeutics Inc SMMT:NASDAQ
RT Quote | Last NYSE Arca, VOL From CTA | USD
After Hours: Last | 7:30 PM EDT14.97
-0.10 (-0.66%)
-0.10 (-0.66%)Volume
29,049
Close
15.07
+0.21 (+1.41%)
+0.21 (+1.41%)Volume
4,308,876
52 week range
13.83 - 30.98
- Open14.75
- Day High15.11
- Day Low14.27
- Prev Close14.86
- 52 Week High30.98
- 52 Week High Date08/05/25
- 52 Week Low13.83
- 52 Week Low Date02/05/26
Latest On Summit Therapeutics Inc
Key Stats
- Market Cap11.697B
- Shares Out776.16M
- 10 Day Average Volume6.62M
- Dividend-
- Dividend Yield-
- Beta-1.30
Latest On Summit Therapeutics Inc
KEY STATS
- Open14.75
- Day High15.11
- Day Low14.27
- Prev Close14.86
- 52 Week High30.98
- 52 Week High Date08/05/25
- 52 Week Low13.83
- 52 Week Low Date02/05/26
- Market Cap11.697B
- Shares Out776.16M
- 10 Day Average Volume6.62M
- Dividend-
- Dividend Yield-
- Beta-1.30
RATIOS/PROFITABILITY
- EPS (TTM)-1.60
- P/E (TTM)-9.40
- Fwd P/E (NTM)-12.55
- EBITDA (TTM)-1.223B
- ROE (TTM)-270.95%
- Revenue (TTM)-
- Gross Margin (TTM)-
- Net Margin (TTM)-271,685.00%
- Debt To Equity (MRQ)-
EVENTS
- Earnings Date08/10/2026(est)
- Ex Div Date-
- Div Amount-
- Split Date-
- Split Factor-
Content From Our Affiliates
Related Video
watch now
Profile
MORESummit Therapeutics Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of patient, physician, caregiver and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. Its lead development candidate is ivonescimab, a novel, potential first-in-class bispecific antibody intending to combine the effects of immunotherapy via a blockade of PD-1...
Robert Duggan
Executive Chairman of the Board, Co-Chief Executive Officer
Mahkam Zanganeh
President, Co-Chief Executive Officer, Director
Manmeet Soni CPA
Chief Financial Officer, Chief Operating Officer, Director
Address
601 Brickell Key Drive, Suite 1000
Miami, FL
33131
United States